ZVRA Zevra Therapeutics
- 4.650
- -0.020-0.43%
- 4.770
- +0.120+2.58%
Zevra Therapeutics News
Retail Investors Account for 59% of Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Ownership, While Institutions Account for 28%
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) First-Quarter Report
The quarterly results for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) were released last week, making it a good time to revisit its performance. Revenues of US$3.4m came in 8.9% below estimates, but
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)
Analysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)
10-Q: Quarterly report
Strong Buy Rating for Zevra Therapeutics Based on Solid Financials and Promising Drug Pipeline
Zevra Therapeutics to Participate at Upcoming Investor Events
CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief
Zevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent With ...
Express News | As of March 31, 2024, Zevra Therapeutics' Cash, Cash Equivalents, And Investments Were $52.7M, April 5, 2024, The Company Announced Refinancing Of Existing Debt With Up To $100M In Committed Capital, Expected To Provide Cash Runway Into 2026
Express News | Zevra Therapeutics Q1 2024 GAAP EPS $(0.40) Beats $(0.48) Estimate, Sales $3.425M Miss $3.764M Estimate
Zevra Therapeutics: Q1 Earnings Snapshot
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M
07:10 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M
Zevra Therapeutics: Cash Runway Into 2026 >ZVRA
Zevra Therapeutics: Cash Runway Into 2026 >ZVRA
Zevra Therapeutics 1Q Loss/Shr 40c >ZVRA
Zevra Therapeutics 1Q Loss/Shr 40c >ZVRA
Zevra Therapeutics 1Q Rev $3.43M >ZVRA
Zevra Therapeutics 1Q Rev $3.43M >ZVRA
Zevra Therapeutics 1Q Loss $16.6M >ZVRA
Zevra Therapeutics 1Q Loss $16.6M >ZVRA
Express News | Zevra Therapeutics Inc Q1 Shr View $-0.48 -- Lseg Ibes Data
Express News | Zevra Therapeutics Inc - Qtrly Shr Loss $0.40
Express News | Zevra Therapeutics Inc - Available Cash, Cash Equivalents and Investments Are Expected to Extend Our Cash Runway Into 2026
Express News | Zevra Therapeutics Inc - Reported Positive Topline Results From Kp1077 Phase 2 Trial in Idiopathic Hypersomnia
Analysis
Price Target
No Data
